Back to top

gene-therapy: Archive

Zacks Equity Research

Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?

KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.

BMYNegative Net Change MRKNegative Net Change ABEONegative Net Change KRYSPositive Net Change

Zacks Equity Research

QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study

uniQure N.V. shares surge nearly 248% after its gene therapy candidate, AMT-130, met key goals in a pivotal Huntington's disease study.

CRMDNegative Net Change QUREPositive Net Change KNSANegative Net Change PHARNegative Net Change

Zacks Equity Research

RARE Reports Positive Long-Term Data From Metabolic Disorder Study

Ultragenyx posts 96-week data showing DTX401 sharply cuts cornstarch needs and improves life quality in GSDIa patients.

RARENegative Net Change CRMDNegative Net Change KNSANegative Net Change PHARNegative Net Change

Zacks Equity Research

Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol

EDIT nominates EDIT-401, a one-time in vivo gene editing therapy, as its lead pipeline candidate to cut the risk of elevated cholesterol.

CRMDNegative Net Change EDITPositive Net Change KNSANegative Net Change PHARNegative Net Change